Alnylam: Alnylam Gets FDA Nod for Expanded Use of Amvuttra in Cardiomyopathy

ALNY secures FDA approval for an sNDA in the United States, seeking the label expansion of Amvuttra to treat ATTR amyloidosis with cardiomyopathy.